Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Clinical practice guidelines for management of neuropathic pain: Expert panel recommendations for South Africa
South African Family Practice, Volume 55, No. 2, Year 2013
Notification
URL copied to clipboard!
Description
Neuropathic pain (NeuP) is challenging to diagnose and manage, despite ongoing improved understanding of the underlying mechanisms. Many patients do not respond satisfactorily to existing treatments. There are no published guidelines for diagnosis or management of NeuP in South Africa. A multidisciplinary expert panel critically reviewed available evidence to provide consensus recommendations for diagnosis and management of NeuP in South Africa. Following accurate diagnosis of NeuP pregabalin, gabapentin, low-dose tricyclic antidepressants (e.g. amitriptyline) and serotonin norepinephrine reuptake inhibitors (duloxetine and venlafaxine) are all recommended as first-line options for the treatment of peripheral NeuP If the response is insufficient after 2 - 4 weeks, the recommended next step is to switch to a different class, or combine different classes of agent. Opioids should be reserved for use later in the treatment pathway, if switching drugs and combination therapy fails. For central NeuP pregabalin or amitriptyline are recommended as first-line agents. Companion treatments (cognitive behavioural therapy and physical therapy) should be administered as part of a multidisciplinary approach. Dorsal root entry zone rhizotomy (DREZ) is not recommended to treat NeuP Given the large population of HIV/AIDS patients in South Africa, and the paucity of positive efficacy data for its management, research in the form of randomised controlled trials in painful HIV-associated sensory neuropathy (HIV-SN) must be prioritised in this country. © Medpharm.
Authors & Co-Authors
Chetty, Sean
South Africa, Johannesburg
University of the Witwatersrand
Baalbergen, E.
South Africa, Cape
Life Vincent Pallotti Rehabilitation Unit
Bhigjee, Ahmed Iqbal G.
South Africa, Durban
The Nelson R. Mandela Medical School
Kamerman, Peter Rowland
South Africa, Johannesburg
University of the Witwatersrand
Ouma, John Richard Bwire
South Africa, Johannesburg
University of the Witwatersrand
Raath, R. P.
South Africa, Pretoria
Jacaranda Hospital
Raff, M.
South Africa, Cape Town
Christiaan Barnard Memorial Hospital
Salduker, S.
South Africa, Durban
St. Augustine's Hospital
Statistics
Citations: 51
Authors: 8
Affiliations: 6
Identifiers
Doi:
10.1080/20786204.2013.10874323
e-ISSN:
20786204
Research Areas
Infectious Diseases
Substance Abuse
Study Design
Randomised Control Trial
Cross Sectional Study
Study Locations
South Africa